Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

ClinicalTrials.gov ID: NCT00080080

Public ClinicalTrials.gov record NCT00080080. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 10, 2026, 10:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the antitumor activity (response rate, time to tumor progression, survival) and safety of docetaxel in combination with talabostat in patients with advanced non-small cell lung cancer (NSCLC) who have failed a prior platinum-containing regimen.

Study identification

NCT ID
NCT00080080
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Point Therapeutics
Industry
Enrollment
Not listed

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Not listed
Primary completion
Not listed
Completion
Not listed
Last update posted
Jun 7, 2007

United States locations

U.S. sites
10
U.S. states
7
U.S. cities
10
Facility City State ZIP Site status
Cancer Center of Florida Ocoee Florida 34761
University of Chicago Chicago Illinois 60637
Van Elslander Cancer Center Grosse Pointe Woods Michigan 48236
New York Oncology/Hematology--Albany Regional Cancer Center Albany New York 12208
Mt. Sinai School of Medicine New York New York 10029
USB Cancer Center-- Nyack Hospital Nyack New York 10960
Dayton Oncology & Hematology Kettering Ohio 45409
Mary Crowley Medical Research Center Dallas Texas 75246
Tyler Cancer Center Tyler Texas 75702
Cancer Care Northwest Spokane Washington 99218

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00080080, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 7, 2007 · Synced Sep 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00080080 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →